Anti-CD40 monoclonal antibody

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C435S069600, C435S326000, C435S332000, C435S334000, C435S343000, C435S343100, C435S346000, C536S023500, C536S023530, C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S153100, C424S173100

Reexamination Certificate

active

10693629

ABSTRACT:
An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.

REFERENCES:
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5786456 (1998-07-01), Ledbetter et al.
patent: 5801227 (1998-09-01), Fanslow, III et al.
patent: 5874082 (1999-02-01), de Boer
patent: 6004552 (1999-12-01), de Boer et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 2004/0120948 (2004-06-01), Mikayama et al.
patent: 0 945 465 (1999-09-01), None
patent: 0 972 445 (2000-01-01), None
patent: 91/09115 (1991-06-01), None
patent: 96/33735 (1996-10-01), None
patent: 96/34096 (1996-10-01), None
patent: 99/39726 (1999-08-01), None
patent: 99/42075 (1999-08-01), None
patent: 99/55369 (1999-11-01), None
patent: 99/61051 (1999-12-01), None
patent: 00/00156 (2000-01-01), None
patent: 00/75348 (2000-12-01), None
patent: 01/16180 (2001-03-01), None
patent: 01/24823 (2001-04-01), None
patent: 01/56603 (2001-08-01), None
patent: 01/83755 (2001-11-01), None
patent: 0183755 (2001-11-01), None
patent: 02/12501 (2002-02-01), None
patent: 02/28904 (2002-04-01), None
patent: 03/029296 (2003-04-01), None
patent: 03/040170 (2003-05-01), None
patent: 03/040170 (2003-05-01), None
Suzuki t al., Transplantation 82 (1 Suppl 2) p. 609, Jul. 15, 2006; Abstract #1624.
Yamada et al., “Generation of Mature Dendritic Cells from a CD14+Cell Line (XS52) by IL-4, TNF-α, IL-1β, and Agonistic Anti-DC40 Monoclonal Antibody”,J. Immunol., 1999; 163(10): 5331-5337, XP002302209.
van Kooten et al., “Functions of CD40 on B cells, dendritic cells and other cells”,Curr. Opin. Immunol., 1997; 9(3): 330-337, XP004313522.
Stout et al., “The many roles of CD40 in cell-mediated inflammatory responses”,Immunol. Today, 1996; 17(10): 487-492, XP004034711.
An et al.; Ligation of CD40 Potentiates Fas-Mediated Activation of the Cysteine Protease CPP32, Cleavage of Its Death Substrate PARP, and Apoptosis in Ramos-Burkitt Lymphoma B Cells; Cellular immunology, vol. 181; 1997; pp. 139-152.
Baccam et al.; Membrane-bound CD154, but not CD40-specific antibody, mediates NF-xB-independent IL-6 production in B cells; Eur. J. Immunol., vol. 29; 1999; pp. 3855-3866.
Barr et al.; Functional activity of CD40 antibodies correlates tot he position of binding relative to CD154; Immunology, vol. 102; 2001; pp. 39-43.
Boon et al.; Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys; Toxicology, vol. 174; 2002; pp. 53-65.
Challa et al.; Epitode-dependent synergism and antagonism between CD40 antibodies and soluble CD40 ligand for the regulation of CD23 expression and lgE synthesis in human B cells; Allergy, vol. 54; 1999; pp. 576-583.
Clark et al.; Activation of human B cells mediated through two distinct cell surfa ce differentiation antigens, Bp35 and Bp50; Proc. Natl. Acad. Sci. USA, vol. 83; Jun. 1986; pp. 4494-4498.
Clark et al.; CDw40 and BLCa-specific monoclonal antibodies detect two distinct molecules which transmit progression signals to human B lymphocytes; Eur. j. Immunol., vol. 18; 1988; pp. 451-457.
de Boer et al.; Generation of monoclonal antibodies to human lymphocyte cell surface antigens using insect cells expressing recombinant proteins; Journal of Immunological Methods, vol. 152; 1992; pp. 15-23.
Diehl et al.; CD40 activationin vivoovercomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy; Nature Medicine, vol. 5, No. 7; Jul. 1999; pp. 774-779.
Dullforce et al; Enhancement of T cell-independent immune responsesin vivoby CD40 antibodies; Nature Medicine, vol. 4, No. 1; Jan. 1998; pp. 88-91.
Erickson et al.; Short-circuiting long-lived humoral immunity byt the heightened engagement of CD40; The Journal of Clinical Investigation, vol. 109, No. 5; Mar. 2002; pp. 613-620.
Francisco et al.; Construction, Expression, and Characterization of BD1-G28-5 sFv, a Single-chain Anti-CD40 Immunotoxin Containing the Ribosome-inactivating Protein Bryodin 1; The Journal of Biological Chemistry, vol. 272, No. 39; Sep. 1997; pp. 24165-24169.
Francisco et al.; Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SBN-14; Cancer Research, vol. 60; Jun. 2000; pp. 3225-3231.
Funakoshi et al.; Inhibition of Human B-Cell Lymphoma Growth by CD40 Stimulation; Blood, vol. 83, No. 10, May 1994; pp. 2787-2794.
Funakoshi et al.; Differential In Vitro and In Vivo Antitumor Effects Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas; Journal of Immunotherapy, vol. 19, No. 2; 1996; pp. 93-101.
Hasbold et al.; Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies; Eur. J. Immunol., vol. 24; 1994; pp. 1835-1842.
Hasbold et al.; Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4; Eur. J. Immunol., vol. 28; 1998; pp. 1040-1051.
Heath et al.; Monoclonal antibodies to murine CD40 define two distinct funtional epitopes; Eur. J. Immunol., vol. 24; 1994; pp. 1828-1834.
Hirano et al.; Inhibition of Human Breast Carcinoma Growth by a Soluble Recombinant Human CD40 Ligand; Blood, vol. 93, No. 9; May 1999; pp. 2999-3007.
Karlsson et al.; Selection of human single chian antibodies against CD40; Immunology Letters, vol. 73, Nos. 2, 3; Sep. 2000; p. 161, abstract No. 358.
Kedl et al.; CD40 stimulation accelerates deletion of tumor-specific CD8+T cells in the absence of tumor-antigen vaccination; PNAS, vol. 98, No. 19; Sep. 2001; pp. 10811-10816.
Kwekkeboom et al.; CD40 plays an essential role in the activation of human B cells by murine EL4B5 cells; Immunology, vol. 79; 1993; pp. 439-444.
Kwekkeboom et al.; Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by cd-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction; Eur. J. Immunol., vol. 24; 1994; pp. 508-517.
Lagerkvist et al.; Single, Anitgen-Specific B Cells Used to Generate FAb Fragments Using CD40-Mediated Amplification or Direct PCR Cloning; BioTechniques, vol. 18, No. 5; 1995; pp. 862, 864-869.
Ledbetter et al.; Augmentation of Normal and Malignant B Cell Proliferation by Monoclonal Antibody to the B Cell-Specific Antigen BP50 (CDW40); The Journal of Immunology, vol. 138, No. 3; Feb. 1987; pp. 788-794.
Ledbetter et al.; Agonistic Activity of a CD40-Specific Single-Chain Fv Constructed from the Variable Regions of mAb G28-5; Critical Reviews in Immunoloby, vol. 17; 1997; pp. 427-435.
Malmborg Hager et al.; Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies; Scandinavian Journal of Immunology, vol. 57; 2003; pp. 517-524.
Maxwell et al.; Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity; The Journal of Immunology, vol. 168; 2002; pp. 4372-4381.
Mazzei et al.; Recombinant Soluble Trimeric CD40 Ligand Is Biologically Activve; The Journal of Biological Chemistry, vol. 270, No. 13; Mar. 1995; pp. 7025-7028.
Murphy et al.; Antibodies to CD40 Prevent Epstein-Barr Virus-Mediated Human B-Cell Lymphomagenesis in Severe Combined Immune Deficient Mice Given Human Peripheral Blood Lymphocytes; Blood, vol. 86, No. 5; Sep. 1995; pp. 1946-1953.
Paulie et al.; A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes; Cancer Immunology Immunotherapy, vol. 20; 1985; pp. 23-28.
Pound et al.; Minimal cross-linking and epitope requirements for Cd40-dependent suppression of apoptosis contrast with those for promotion of the cell cycle and homotypic adhesions in human B cells; International Immunology, vol. 11, No. 1; 1999; pp. 11-20.
Rolink et al.; The SCID but Not theRAG-2 Gene Product Is Required for Sμ-Sε Heavy Chain Class Switching; Immunity, vol. 5; Oct. 1996; pp. 319-330.
Romano et al.; Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells; Blood, vol. 92, No. 3; Aug. 1998; pp. 990-995.
Schoenberger et al.; T-cell help for cytotoxic T ly

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-CD40 monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-CD40 monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD40 monoclonal antibody will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3772751

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.